MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce the appointment of veteran healthcare industry leader Jeffrey Morris as Vice President of Sales and Marketing.
With over 20 years of experience, Mr. Morris has worked for some of the most recognized global healthcare and pharmaceutical brands such as Pfizer Inc., Boehringer-Ingelheim Canada, Merck Canada Inc., Novartis Vaccines and Sanofi Pasteur. Mr. Morris brings a strong track record of establishing new territory clinic and physician relationships, implementing and leading large-scale sales and marketing teams and driving sales results.
“I am honoured to be joining MedX Health at this pivotal stage of growth for the company,” said Jeffrey. “With our unique teledermatology technology platform, I look forward to establishing MedX as an industry leader.”
“We are very pleased to have Jeffrey join our team,” said Stephen Lockyer, Chief Executive Officer of MedX Health. “We searched for a recognized health-care executive in the diagnostics space, a leader with proven sales and marketing expertise, one who is results driven and up to the task of building a strong team at MedX. Jeffrey met all of those criteria, and we are glad to have him aboard. He will be a critical part of our success.”
MedX’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image-capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface. Teledermatology, is a subspecialty of dermatology that offers safe and effective virtual patient assessment and diagnosis at a distance, eliminating the need for in-person appointments.
About MedX Health Corp.:
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Contacts
Bill Mitoulas, Investor Relations
MedX Health Corp.
[email protected]
+1-416-479-9547